Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-29T02:56:57.509Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode

Published online by Cambridge University Press:  16 April 2020

JP Bocksberger ,
JP Gachoud ,
J Richard  and
Ρ Dick
JP Bocksberger
Affiliation:
Clinique universitaire de Psichiatrie gériatrique, IUPG, 1225 Geneva
JP Gachoud
Affiliation:
Roche Pharma (Schweiz) AG, 4153 Reinach, Switzerland
J Richard
Affiliation:
Clinique universitaire de Psichiatrie gériatrique, IUPG, 1225 Geneva
Ρ Dick
Affiliation:
Clinique universitaire de Psichiatrie gériatrique, IUPG, 1225 Geneva
Get access

Summary

In a double-blind study carried out on elderly patients (older than 65 years) the efficacy and tolerability of the new antidepressant moclobemide was compared. Moclobemide belongs to a new class of substances called RIMA (Reversible inhibitor of the monoamine oxidase type A). Fluvoxamine, a selective reuptake-inhibitor of 5-HT, belongs to a class of antidepressants known for their better tolerability compared to tricyclic especially with elderly patients. Forty elderly patients (mean age 75 years) with major depression (according to DSM III) were randomized to receive either moclobemide (300 mg) or fluvoxamine (100 mg) twice daily. Dosages were increased when necessary on day 8, to a maximum of 450 mg moclobemide or 200 mg fluvoxamine and in most cases were maintained at these levels for the remainder of the study period (four weeks). Moclobemide was more effective than fluvoxamine showing a marked antidepressant effect and an earlier effect on psychomotor retardation. The two drugs were well tolerated showing a low incidence of side effects.

Keywords

moclobemidefluvoxamineRIMAmajor depressionelderlyMADRSWidlöcher retardation scalegeriatric psychiatry
Type
Original article
Information
European Psychiatry , Volume 8 , Issue 6 , 1993 , pp. 319 - 324
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Burkhard, WP, Bonetti, EP, Da Prada, M, Martin, JR, Polc, Ρ (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248, 391–399Google Scholar
Claassen, V, Davies, JE, Hertting, G, Placheta, Ρ (1977) Fluvoxamine, a specific 5-hydroxythryptamine uptake inhibitor. Br J Pharmacol 60, 505–516CrossRefGoogle Scholar
Da Prada, M, Kettler, R, Keller, HH, Burkard, WP, Muggli-Maniglio, D, Haefely, WE (1989) Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248, 400–414Google ScholarPubMed
De Wilde, JE, Mertens, C, Wakelin, JS (1963) Clinical trials of fluvoxamine versus chlorimipramine with single and three times daily dosing. Br J Clin Pharmacol 15, 427S–431SCrossRefGoogle Scholar
Guelfi, JD, Dreyfus, JF, Pichot, Ρ (1983) A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 15, 411S–417SCrossRefGoogle ScholarPubMed
Lecrubier, Y, Guelfi, JD (1990) Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiatr Scand 82 (suppl 360) 18–23CrossRefGoogle Scholar
Montgomery, SA, Asberg, M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatr 134, 382–389CrossRefGoogle ScholarPubMed
Versiani, M, Nardi, AE, Figueira, ILV, Stabl, M (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand 82 (suppl 360) 24–28CrossRefGoogle Scholar
Widlöcher, D (1983) Le Ralentissement Dépressif. Nodules Presses Universitaires de France, ParisGoogle Scholar
Wilson, WH, Higano, H, Papadatos, Y, Kelwala, S, Ban, TA (1983) A double-blind placebo controlled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 15, 385S–392SCrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.